Skip to search formSkip to main contentSkip to account menu

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… 
National Institutes of Health

Related topics

Related topics

2 relations
IDEC-In2B8/rituximabIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
BackgroundThe purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab… 
Review
2010
Review
2010
Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics
Section I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future… 
2009
2009
Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma
There is no data about the efficacy and safety of radioimmunotherapy with 90Y‐ibritumomab tiuxetan in patients with relapsed or… 
2008
2008
Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
UNLABELLED The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in… 
Review
2006
Review
2006
Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
Review
2006
Review
2006
Yttrium 90 ibritumomab tiuxetan in lymphoma
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma… 
2005
2005
Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem…
Radioimmunotherapy (RIT) has demonstrated high clinical efficacy in the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and… 
2004
2004
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase…
Presently, there is no standard second-line regimen for patients (pts) with diffuse large B-cell lymphoma (DLBCL) who cannot… 
Review
2004
Review
2004
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Yttrium 90-labeled ibritumomab tiuxetan is approved for the treatment of patients with relapsed or refractory low-grade… 
Review
2003
Review
2003
Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma
Among the monoclonal antibodies (mAbs) under clinical development, anti-CD20 mAbs have been most extensively investigated and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)